Who are SPMC 2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NPC-16 Standard Dosing Regimen Group, Fp MDPI, NPC-16 Continuous Dosing Regimen Group, SPM 962, TVP-1012, Aplause®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/spmc-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

SPMC 2 — Competitive Intelligence Brief

SPMC 2 (SPMC 2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sphingosine-1-phosphate receptor 1 (S1PR1) modulator. Area: Autoimmune diseases.

phase 3 Sphingosine-1-phosphate receptor 1 (S1PR1) modulator S1PR1 Autoimmune diseases Small molecule Live · refreshed every 30 min

Target snapshot

SPMC 2 (SPMC 2) — Korea University Anam Hospital. SPMC 2 is a small molecule that targets the Sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SPMC 2 TARGET	SPMC 2	Korea University Anam Hospital	phase 3	Sphingosine-1-phosphate receptor 1 (S1PR1) modulator	S1PR1
NPC-16 Standard Dosing Regimen Group	NPC-16 Standard Dosing Regimen Group	Nobelpharma	phase 3	S1P receptor modulator	S1PR1
Fp MDPI	Fp MDPI	Teva Branded Pharmaceutical Products R&D, Inc.	phase 3	S1P receptor modulator	S1PR1
NPC-16 Continuous Dosing Regimen Group	NPC-16 Continuous Dosing Regimen Group	Nobelpharma	phase 3	S1P receptor modulator	S1PR1
SPM 962	SPM 962	Otsuka Pharmaceutical Co., Ltd.	phase 3	S1P receptor modulator	S1PR1
TVP-1012	TVP-1012	Takeda	phase 3	S1P receptor modulator	S1PR1
Aplause®	Aplause®	Phytopharm Consulting Brazil	phase 3	S1P receptor modulator	S1PR1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sphingosine-1-phosphate receptor 1 (S1PR1) modulator class)

Korea University Anam Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SPMC 2 — Competitive Intelligence Brief. https://druglandscape.com/ci/spmc-2. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab